More Osteoporosis Patients Stay On Treatment With Effective Once-Monthly Bonviva(R) Treatment Programme Versus Weekly Alendronate Part 5

2. Cowell W, Fulford-Smith A, Poultney S. Adherence lath awake to bisphosphonate running all for osteoporosis inwardly UK patients. Poster presented the second communal audience of the European Calcified Tissue Society and the International Bone Mineral Society, Geneva, 25-29 June 2005.

3. Cramer J, Amonkar M, Hebborn A, Altman R. Compliance and Persistence with Bisphosphonate Dosing Regimens Among Women with Postmenopausal Osteoporosis. Current Medical Research and Opinions 2005; 21(9): 1453-60.

4. Sebaldt R, Shane LG, Pham BZ, Cook RJ, Thabane L. et al. Impact of non-compliance and non-persistence with day by day bisphosphonates with longer-term prosperity outcome in patients with osteoporosis treat in tertiary authority limelight. J Bone Miner Res 2004;19 (Suppl. 1): (Abstract M423) 5. Siris E, Rosen CJ, Harris ST, Abbott TA, Barr CE, Silverman S. Adherence to bisphosphonate psychiatric aid: similarity to distil fracture at 24 months in women with postmenopausal osteoporosis.

Abstract 397, oral and mouth reading at: Sixth International Symposium on Osteoporosis, National Osteoporosis Foundation, April 7, 2005, Washington, DC 6. Goettsch et al. Risk for osteoporotic fractures be reduced in annoying bisphosphonate user. J Bone Miner Res 2005;20(Suppl. 1):S278 (Abstract SU388) 7. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of respect with osteoporosis therapy on fracture rates in actual dummy run. Osteoporos Int 2004;15:1003-8.

8. Kanis JA, Delmas P, Burckhardt P, et al. (1997) Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int1997; 7:390.

Scientific research that supports this view be published this year contained by the article Arthritis and Rheumatism. "Our solid findings have a break cut that women who be depressed are also losing their suffer of bouquet, and may overcompensate with using more perfume," explain investigator Prof. Yehuda Shoenfeld, a extremity of the Sackler Faculty of Medicine at Tel Aviv University.

10. Benhamou C-L, Licata AA, Devas V, Masanauskaite D, Hadji P. Patient preference for once-monthly oral ibandronate and weekly oral alendronate in postmenopausal osteoporosis: the BALTO study. Abstract presented at 33rd European Symposium of Calcified Tissue, Prague, Czech Republic 10-14 May 2006.

11. Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA et al. Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis.

Journal of Bone & Mineral Research 2004;19(8):1241-49.

12. McClung MR, Drezner MK, Reginster J-Y, Bolognese M, Hughes C et al. Once-Monthly Oral Ibandronate Is At Least As Effective As Daily Oral Ibandronate In Postmenopausal Osteoporosis: 2-Year Findings from MOBILE . Abstract presented at 27th Annual Meeting of the American Society of Bone and Mineral Research, Nashville, USA 23 - 27 September 2005.